Elmiron linked to Pigmentary Maculopathy
For years, pentosan polysulfate sodium (Elmiron) was the only oral medication approved for interstitial cystitis, a painful bladder condition affecting hundreds of thousands of patients. By 2026, the drug's association with pigmentary maculopathy—a progressive retinal disease that can lead to irreversible vision loss—has reshaped both clinical practice and pharmaceutical liability. We now see a clear trajectory from initial case reports to mass tort litigation, and the evidence continues to mount.
From Interstitial Cystitis to Retinal Toxicity: The Elmiron Timeline
The first major signal emerged in 2018 when Dr. Nieraj Jain and colleagues at Emory University published a case series linking long-term Elmiron use to a distinct pattern of pigmentary maculopathy. By 2020, the FDA required a new warning label. In 2026, the link is undisputed: cumulative exposure—typically exceeding 1,500 grams over several years—carries a dose-dependent risk. Our table below summarizes the key milestones:
| Year | Event | Clinical/Legal Impact |
|---|---|---|
| 1996 | FDA approval of Elmiron for interstitial cystitis | No retinal toxicity warning |
| 2018 | Jain et al. publish first case series (6 patients) | Initial signal of pigmentary maculopathy |
| 2020 | FDA adds warning to label | Baseline eye exams recommended |
| 2022 | Multidistrict litigation (MDL) consolidated in New Jersey | Over 1,000 lawsuits filed |
| 2024 | First bellwether trials produce mixed verdicts | Plaintiffs win in some cases; defense in others |
| 2026 | Ongoing MDL; retinal screening now standard of care | Janssen faces continued exposure |
Why the MDL Against Janssen Pharmaceuticals Still Matters
The multidistrict litigation, In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation (MDL No. 2973), remains active in the District of New Jersey. Plaintiffs argue that Janssen (a Johnson & Johnson subsidiary) knew or should have known about the retinal risks years before the first public reports. Internal documents from the 2000s reportedly show that company scientists observed retinal pigment epithelial changes in animal studies—yet no warning was issued to prescribers.
We have tracked the discovery process closely. Key evidence includes:
- Pre-2018 internal emails discussing "retinal pigmentation" in canine toxicology studies
- Failure to conduct post-market surveillance for ocular adverse events
- Marketing materials that emphasized safety without mentioning vision risks
The bellwether trials have been instructive. In one 2024 verdict, a jury awarded $4.7 million to a woman who developed advanced maculopathy after 15 years of Elmiron use. Another trial ended in defense verdict when the plaintiff could not prove cumulative dose exceeded 1,000 grams. These outcomes underscore the importance of detailed medication histories in litigation.
"The Elmiron story is a textbook case of delayed drug safety signals. Patients were told for decades that the drug was safe, while the company had data suggesting otherwise. Our 2026 position is clear: any patient who took Elmiron for more than two years should have a comprehensive dilated eye exam, and those with visual symptoms should be evaluated by a retinal specialist."
— Source context: DayWilliams.com analysis; reference archives at Wayback Machine archive and current site at daywilliams.com.
Clinical Screening Protocols in 2026: What Every Prescriber Must Know
By 2026, the standard of care for Elmiron users has evolved dramatically. The American Urological Association now recommends baseline optical coherence tomography (OCT) and fundus autofluorescence imaging before starting therapy, with annual re-evaluation. For patients who have already taken the drug, the screening protocol is even more aggressive:
- Immediate retinal exam for anyone with visual complaints (blurry vision, difficulty reading, prolonged dark adaptation)
- Multifocal ERG for ambiguous cases
- Discontinuation of Elmiron if any pigmentary changes are detected—even without visual symptoms
We have seen a measurable decline in new Elmiron prescriptions since 2020, down approximately 60% according to IQVIA data. Alternative treatments for interstitial cystitis—including amitriptyline, hydroxyzine, and bladder instillations—have filled the gap. Yet thousands of patients remain on the drug, often because they have failed other therapies. For these individuals, the risk-benefit calculus must be documented in writing, with explicit acknowledgment of ocular risks.
The medicolegal implications are profound. In 2026, a failure to screen an Elmiron patient for maculopathy is itself a potential basis for malpractice. We have consulted on several cases where primary care physicians prescribed the drug without any eye exam referral—and the patient later developed bilateral vision loss. These cases settle quickly, but they highlight a systemic failure in medication safety communication.